English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  To determine the prognostic value of isocitrate dehydrogenase 1 ( IDH1 ) mutation,  O  6 -methylguanine-DNA methyltransferase ( MGMT ) promoter methylation, and 1p/19q co-deletion in Japanese patients with malignant gliomas.    Methods  We studied 267 malignant gliomas, which included 171 glioblastomas (GBMs), 40 anaplastic astrocytomas (AAs), 30 anaplastic oligodendrogliomas (AOs), and 26 anaplastic oligoastrocytomas (AOAs). These malignant gliomas were divided into 2 groups (Group 1: GBM + AA, Group 2: AO + AOA) according to the presence of the oligodendroglioma component. We examined  IDH1  mutation and  MGMT  promoter methylation in each group by direct sequencing and methylation-specific PCR, respectively. We further examined 1p/19q co-deletion in Group 2 by fluorescence in situ hybridization. Survival between groups was compared by Kaplan–Meier analysis.    Results  In Group 1, patients with  IDH1  mutations exhibited a significantly longer survival time than patients with wild-type  IDH1 . However, no significant difference was observed in Group 2, although patients with  IDH1  mutations tended to show prolonged survival. For both Group 1 and Group 2, patients with  MGMT  methylation survived longer than those without this methylation. Further, patients with 1p/19q co-deletion showed significantly better outcome in Group 2.    Conclusions  Our study confirms the utility of  IDH1  mutations and  MGMT  methylation in predicting the prognosis of Group 1 patients (GBM + AA) and demonstrated that  IDH1  mutations may serve as a more reliable prognostic factor for such patients. We also showed that  MGMT  methylation and 1p/19q co-deletion rather than  IDH1  mutations were prognostic factors for Group 2 patients (AOA + AO). Our study suggests that patients survive longer if they have  IDH1  mutations and undergo total resection. Further, irrespective of  MGMT  promoter methylation status, the prognosis of glioma patients can be improved if total resection is performed. Moreover, our study includes the largest number of Japanese patients with malignant gliomas that has been analyzed for these three markers. We believe that our findings will increase the awareness of oncologists in Japan of the value of these markers for predicting prognosis and designing appropriate therapeutic strategies for treating this highly fatal disease.

world journal of surgical oncology

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients